Research Article
Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis
Table 1
Inflammatory markers.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Values shown are mean (± SD) ng/mL. —comparison between patients at baseline and healthy controls. —comparison between patients at three months on Natalizumab therapy and healthy controls. —comparison between patients at baseline and at three months on Natalizumab therapy. —comparison between patients at baseline and at six months of Natalizumab therapy. |